Can CRd be a standard for refractory myeloma?

Abstract

In this issue of Blood, Wang et al describe that the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) can be a valuable option in relapsed and refractory multiple myeloma patients. © 2013 by The American Society of Hematology.